Olivier Loeillot - Mar 3, 2025 Form 4 Insider Report for REPLIGEN CORP (RGEN)

Role
Chief Executive Officer, Director
Signature
/s/ Marc Baumgartner (Attorney in Fact)
Stock symbol
RGEN
Transactions as of
Mar 3, 2025
Transactions value $
$0
Form type
4
Date filed
3/4/2025, 01:18 PM
Previous filing
Feb 28, 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RGEN Common Stock Award $0 +14.5K +44.95% $0.00 46.7K Mar 3, 2025 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RGEN Stock Option (Right to Buy) Award $0 +13.6K $0.00 13.6K Mar 3, 2025 Common Stock 13.6K $155.38 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Mr. Loeillot was awarded 14,480 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of Repligen Corporation's Common Stock. The restricted stock units vest in equal annual instalments over a three-year period beginning on the first anniversary of the grant date. The restricted stock units may be settled only by delivering shares of Repligen Corporation's Common Stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance.
F2 One third of the stock options will vest and become exercisable annually on March 3, 2026, March 3, 2027, and March 3, 2028.